GW's Epidyolex (cannabidiol) Receives MHRA's Approval for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in UK
Shots:
- The approval is based on P-III safety & efficacy study that evaluates Epidyolex (25 mg/kg/day) vs PBO in patients aged ≥2yrs. as an adjunctive treatment with seizures associated with TSC
- The study met its 1EPs i.e.- reduction in seizure frequency (49% vs 27%). The 2EPs had supported the effects on 1EPs & safety profile was consistent with previous studies results with no new safety risks observed
- Epidyolex will be available in England- Wales- and Scotland & follows the recent approval in all 27 countries of the EU along with Norway- Iceland & Liechtenstein. The approval marks the 4th indication of the drug in the UK & the therapy received EMA’s ODD for seizures associated with LGS- Dravet syndrome & TSC
| Ref: Jazz Pharmaceuticals | Image: GW Pharma
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com